Fri, 27th Jul 2018 12:52
LONDON (Alliance News) - Pharmeceutical company Proteome Sciences PLC said Friday that Vulpes Life Sciences Fund purchased 171,000 shares at a price of 2.85 pence per share on Wednesday.
Shares in Proteome were up 15% at 3.55 pence on Friday.
Following the transaction, Vulpes now holds a direct and indirect interest in 55.4 million shares, reflecting a 19% stake in the company.
Martin Diggle, a director at both Vulpes and Proteome, now holds an interest in all 55.4 million shares.
Proteome Sciences PLC - London-based protein-focused drug development services provider - Proteome tells annual general meeting on Thursday it is "con...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
(Alliance News) - Proteome Sciences PLC on Friday said it won a contract from an unnamed US biopharmaceutical company to use Proteome's mass spectrome...
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's ma...
Proteome (PRM)